Clinical trial NCT05590364: Aesthetic Performance and Tolerance of an Injective Intradermal Treatment for the Skin Roughness and Laxity of Back of the Hands
Official title: Interventional, Post-marketing, Local, Mono-centric Study for Evaluation of Aesthetic Performance and Tolerance of an Injective Intradermal Treatment for the Skin Roughness and Laxity of Back of the Hands
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Skin Laxity
Skin Roughness
Keywords: Skin laxity
Skin roughness
Profhilo Body
Hyaluronic Acid
Hybrid Cooperative Complexes
Lead sponsor: IBSA Farmaceutici Italia Srl
Sponsor class: INDUSTRY
Collaborators: name: Derming SRL
First posted: 2022-10-21
Enrollment: 51
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: 55 subjects undergoing Profhilo Body treatment in the back of the hands, 3 visits: Day 0 (treatment) Day 30 (1 month after Day 0 treatment) Day 120 (4 months after Day 0 - follow-up).
Primary purpose: TREATMENT

Brief summary: People lose collagen all over the body, not just in the face; skin roughness and laxity of the dorsum of the hands can result from chrono and photo-aging. This skin roughness and laxity can range from very mild to severe; injection procedures can provide new tone and firmness to the skin of the hand dorsum. Dermal fillers are the most used non-permanent injectable materials available today to correct skin flaccidity and roughness on the dorsum of the hands. They give immediate aesthetic effect due to elastic gel matrix injected and impart longer term effects due to bio stimulation, promoting new collagen formation. The objective of this study is to investigate the aesthetic performance of the Hyaluronic acid (HA)- based dermal filler Profhilo® Body injected by a blunt tip microcannula (25G or 22G, preferably 22G), with fanning technique through a single entry point performing 5 passages and injecting 0,3 ml per passage, 1,5 ml for each hand. Volunteers of both sexes, aged 18-65 years with mild-moderate skin roughness and laxity at the level of hand dorsum are to be treated.

Detailed description: Open, monocentric. 3 visits, 55 subjects.

Primary endpoint of the study is the evaluation of performance and tolerance of Profhilo Body (3ml) treatment in the back of the hands ( or dorsum of the hands). Secondary endpoint is self-assessment questionnaire by both doctors and volunteers.

Profhilo® Body (IBSA Farmaceutici Italia S.r.l.) is a resorbable medical device 3.25 ml non-pyrogenic pre-filled syringe, containing 3 ml of 3.2% hyaluronic acid for intradermal use (48 mg H-HA + 48 mg L-HA) dissolved in 3 ml of saline buffered sodium chloride. - IBSA Farmaceutici Italia S.r.l. - ITALY. The principle component is cross-linked Hyaluronic Acid of non-animal origin, produced by bacterial fermentation.

Eligibility criteria: Inclusion Criteria: Will be included in the study volunteers with the following characteristics:

* female and male sex, not necessarily 1:1 ratio;
* age 18-65 years;
* asking for hands restoration;
* available and able to return to the study site for the post-procedural follow-up examinations;
* accepting to not change their habits regarding food, physical activity, cosmetic and cleansing products for the hands;
* accepting not to expose their hands to strong UV irradiation (UV session, or sun bathes) during the entire duration of the study, without appropriate sun protection;

Exclusion Criteria:

* Pregnancy;
* lactation;
* smokers;
* alcohol or drug abusers;
* subjects not in menopause who do not use adequate contraceptive precautions in order to avoid pregnancies during the study;
* Body Mass Index (BMI) variation (± 1) during the study period;
* performing non-surgical skin aesthetic procedures for hands in the 6 months prior to the study start;
* aesthetic surgical procedure for the hands in the past;
* change in the normal habits regarding food, physical activity, cosmetic products and cleansing for the hands during the month preceding the test;
* sensitivity to the test product or its ingredients (to be assessed by the investigator during the baseline visit);
* subjects whose insufficient adhesion to the study protocol is foreseeable;
* participation in a similar study currently or during the previous 6 months.)
* presence of cutaneous disease on the tested area, as lesions, scars, malformations;
* clinical and significant skin condition on the test area (e.g. active eczema, psoriasis, sclerodermia, local infections).

Exclusion criteria due to systemic disease:

* Diabetes;
* endocrine disease;
* hepatic disorder;
* renal disorder;
* cardiac disorder;
* pulmonary disease;
* cancer;
* neurological or psychological disease;
* inflammatory/immunosuppressive disease;
* drug allergy Exclusion criteria due to ongoing pharmacological treatment
* Anticoagulants and antiplatelet drugs, anti-histaminic, topic and systemic corticosteroids, narcotic, antidepressant, immunosuppressive drugs (with the except of contraceptive or hormonal treatment starting more than 1 year ago);
* using of drugs able to influence the test results in the investigator opinion. The use of other drugs, not mentioned above, can be authorized by the Investigator. The trade name, the dosage, the start and stop date of the therapy will be reported on concomitant medication form.

Primary outcomes:
measure: Change from Baseline of Skin Roughness and flaccidity at 30 days and at 120 days post-injection
timeFrame: Day 0, Day 30, Day 120
measure: Change from Baseline of Skin density (profilometry) at 30 days and at 120 days post-injection
timeFrame: Day 0, Day 30, Day 120
measure: Change from Baseline of Superficial and deep skin plastoelasticity at 30 days and at 120 days post-injection
timeFrame: Day 0, Day 30, Day 120
measure: Change from Baseline of Tissue dielectric constant value of superficial and deep skin layers at 30 days and at 120 days post-injection
timeFrame: Day 0, Day 30, Day 120
measure: Change from Baseline of Photographic evaluation at 30 days and at 120 days post-injection
timeFrame: Day 0, Day 30, Day 120
Secondary outcomes:
measure: Efficacy questionnaire
timeFrame: Day 30, Day 120
measure: Treatment tolerance questionnaire
timeFrame: Day 30, Day 120
Other outcomes:
Locations:
city: Milano
country: Italy
facility: DERMING S.r.l., Clinical Research and Bioengineering Institute
state: Lombardia
Study officials:
affiliation: DERMING S.r.l., Clinical Research and Bioengineering Institute
name: Adele Sparavigna, MD
role: PRINCIPAL_INVESTIGATOR
References: